Antiretroviral drugs in the perinatal period
This presentation is the property of its rightful owner.
Sponsored Links
1 / 20

ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD PowerPoint PPT Presentation


  • 45 Views
  • Uploaded on
  • Presentation posted in: General

ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD. Use of ARV Drugs by HIV-Infected Pregnant Women and Their Infants. Considerations for choice of ARV drugs for pregnant women include: Possible changes in dosing requirements resulting from physiologic changes associated with pregnancy

Download Presentation

ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Antiretroviral drugs in the perinatal period

ANTIRETROVIRAL DRUGS INTHE PERINATAL PERIOD


Use of arv drugs by hiv infected pregnant women and their infants

Use of ARV Drugs by HIV-Infected Pregnant Women and Their Infants

  • Considerations for choice of ARV drugs for pregnant women include:

    • Possible changes in dosing requirements resulting from physiologic changes associated with pregnancy

    • Potential exacerbation of ARV drug toxicities

    • Pharmacokinetics and toxicity of transplacentally transferred drugs

    • Potential short- and long-term effects of ARV drugs on fetuses and newborns

www.aidsetc.org


Combination art and pregnancy outcome

Combination ART and Pregnancy Outcome

  • Possible small increased risk of preterm birth in pregnant women receiving protease inhibitor (PI)-based ART; however, given the clear benefits, PIs should not be withheld for fear of altering pregnancy outcome. (AII)

www.aidsetc.org


Pharmacokinetic changes

Pharmacokinetic Changes

  • Altered dosing during pregnancy may be required for some PIs, such as lopinavir/ritonavir. (AII)

    • Concentrations of the following drugs are reduced during the 2nd and/or 3rd trimesters

      • Lopinavir/ritonavir (LPV/r)

      • Atazanavir (ATV)

      • Darunavir (DRV)

      • Nelfinavir (NFV)

    • The need for dosage adjustment depends on the patient’s treatment experience and use of concomitant medications.

www.aidsetc.org


Teratogenicity

Teratogenicity

  • Women of childbearing potential should undergo pregnancy testing before initiating efavirenz(EFV) and receive counseling about the potential risk to the fetus and desirability of avoiding pregnancy while on EFV. (AIII)

  • Consider non-EFV regimens in patients who are: (BIII)

    • Planning to become pregnant

    • Sexually active and not using effective contraception

www.aidsetc.org


Antiretroviral drugs in the perinatal period

Report all cases of ARV use in pregnant women to the Antiretroviral Pregnancy Registry: http://www.APRegistry.com(AIII)

The registry collects observational, nonexperimental data regarding ARV exposure during pregnancy to assess potential teratogenicity.

www.aidsetc.org

August 2012


Nevirapine and hepatic rash toxicity

Nevirapine and Hepatic/Rash Toxicity

  • Avoid initiating NVP in women with CD4 counts >250 cells/µL unless the benefits outweigh the risks. (AII)

    • Risk of hepatotoxicity/hypersensitivity reaction

  • Women who are tolerating NVP-containing regimens and become pregnant can continue regardless of CD4 count. (AII)

www.aidsetc.org


Nrti drugs and mitochondrial toxicity

NRTI Drugs and Mitochondrial Toxicity

  • The combination of stavudine (d4T) and didanosine (ddl) should not be prescribed during pregnancy because of reports of lactic acidosis and maternal/neonatal mortality with prolonged use during pregnancy. (AII)

  • Mitochondrial dysfunction should be considered in uninfected children with perinatal exposure to ARV drugs who present with severe clinical findings, particularly neurologic. (AII)

  • Long-term clinical follow-up is recommended for any child with in utero exposure to ARV drugs. (AIII)

www.aidsetc.org


Protease inhibitors and hyperglycemia

Protease Inhibitors and Hyperglycemia

  • HIV-infected women taking ARV regimens during pregnancy should undergo standard glucose screening at 24-28 weeks’ gestation. (AIII)

  • Owing to linkage with hyperglycemia:

    • Consider earlier glucose screening in women receiving PI-based regimens initiated before pregnancy. (BIII)

www.aidsetc.org


Nucleoside and nucleotide reverse transcriptase inhibitors 1

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (1)

www.aidsetc.org


Nucleoside and nucleotide reverse transcriptase inhibitors 2

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (2)

www.aidsetc.org


Nucleoside and nucleotide reverse transcriptase inhibitors 3

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (3)

www.aidsetc.org


Nucleoside and nucleotide reverse transcriptase inhibitors 4

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (4)

www.aidsetc.org


Nonnucleoside reverse transcriptase inhibitors nrtis 1

Nonnucleoside Reverse Transcriptase Inhibitors (NRTIs) (1)

www.aidsetc.org


Nonnucleoside reverse transcriptase inhibitors nrtis 2

NonnucleosideReverse Transcriptase Inhibitors (NRTIs) (2)

www.aidsetc.org


Nonnucleoside reverse transcriptase inhibitors nrtis 3

NonnucleosideReverse Transcriptase Inhibitors (NRTIs) (3)

www.aidsetc.org


Protease inhibitors 1

Protease Inhibitors (1)

Class concerns for PIs: hyperglycemia, diabetes, question of increased risk of preterm delivery

www.aidsetc.org


Protease inhibitors 2

Protease Inhibitors (2)

www.aidsetc.org


Protease inhibitors 3

Protease Inhibitors (3)

www.aidsetc.org


Additional recommendations by class

Additional Recommendations by Class

Integrase Inhibitors

Entry Inhibitors

www.aidsetc.org


  • Login